Provided are methods for clinical treatment of an ADAMTS 13 deficiency by administering an anti-C5 antibody, or antigen binding fragment thereof. Also, provided are methods for clinical treatment of congenital Thrombotic Thrombocytopenic Purpura by administering an anti-C5 antibody, or antigen binding fragment thereof.